Last reviewed · How we verify

Attruby — Competitive Intelligence Brief

Attruby (ACORAMIDIS) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Cardiovascular.

marketed Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Attruby (ACORAMIDIS) — Bridgebio Pharma. Attruby works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Attruby TARGET ACORAMIDIS Bridgebio Pharma marketed 2024-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Attruby — Competitive Intelligence Brief. https://druglandscape.com/ci/acoramidis. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: